CRCM  Vol.2 No.9 , December 2013
Osteonecrosis of the jaw in a patient taking once-yearly infusion of zoledronic acid for osteopenia
Abstract: Osteonecrosis of the jaw (ONJ) is an adverse effect of nitrogen-containing bisphosphonates. Advancing age, intravenous administration of zoledronic acid (ZOL), history of dento-alveolar surgery, and concomitant systemic diseases such as diabetes are known as risk factors for developing ONJ. However, despite numerous studies, the exact pathophysiology remains unclear and management strategies are largely anecdotal. Once-yearly intravenously administered 5 mg ZOL was approved by the US Food and Drug Administration in 2007 for the treatment of osteoporosis and its efficacy with 3 year-regimen had been recently proven in preventing new clinical fracture. Although occurrences of ONJ have been reported to be rare with this drug administration, available data is very limited and long-term outcomes are lacking. We present a case of ONJ identified in an osteopenic patient with an intermittent but long standing sore mouth related to exposed mandibular bone. Once-yearly infusion of zoledronic acid used in the treatment of osteopenia may contribute to the spontaneous development of ONJ, especially in those presenting with multiple comorbidity factors. This report suggests the importance of health care professionals keeping abreast of new developments in this area and providing appropriate information to their patients.
Cite this paper: Tanaka, T. and Taylor, C. (2013) Osteonecrosis of the jaw in a patient taking once-yearly infusion of zoledronic acid for osteopenia. Case Reports in Clinical Medicine, 2, 535-537. doi: 10.4236/crcm.2013.29139.

[1]   Marx, R.E. (2003) Pamidronate (aredia) and zoledronate (zometa) induced avascular necrosis of the jaws: A growing epidemic. Journal of Oral and Maxillofacial Surgery, 61, 1115-1117.

[2]   Lo, J.C., O’Ryan, F.S., Gordon, N.P., et al. (2010) Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure. Journal of Oral and Maxillofacial Surgery, 68, 243-253.

[3]   Boonen, S., Black, D.M., Colon-Emeric, C.S., et al. (2010) Efficacy and safety of a once-yearly intravenous zoledronic acid 5 mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older. Journal of the American Geriatrics Society, 58, 292-299.

[4]   Grbic, J.T., Black, D.M., Lyles, K.W., et al. (2010) The incidence of osteonecrosis of the jaw in patients receiving 5 milligrams of zoledronic acid: Data from the health outcomes and reduced incidence with zoledronic acid once yearly clinical trials program. Journal of the American Dental Association, 141, 1365-1370.

[5]   Woo, S.B., Hellstein, J.W. and Kalmar, J.R. (2006) Narrative [corrected] review: Bisphosphonates and osteonecrosis of the jaws. Annals of Internal Medicine, 144, 753-761.

[6]   Popovic, K.S. and Kocar, M. (2010) Imaging findings in bisphosphonate-induced osteonecrosis of the jaws. Radiology and Oncology, 44, 215-219.

[7]   O’Ryan, F.S. and Lo, J.C. (2012) Bisphosphonate-related osteonecrosis of the jaw in patients with oral bisphosphonate exposure: Clinical course and outcomes. Journal of Oral and Maxillofacial Surgery, 70, 1844-1853.

[8]   Hellstein, J.W., Adler, R.A., Edwards, B., et al. (2011) Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: Executive summary of recommendations from the American dental association council on scientific affairs. Journal of the American Dental Association, 142, 1243-1251.

[9]   Khamaisi, M., Regev, E., Yarom, N., et al. (2007) Possible association between diabetes and bisphosphonate-related jaw osteonecrosis. Journal of Clinical Endocrinology & Metabolism, 92, 1172-1175.

[10]   Wong, N.S., Buckman, R.A., Clemons, M., et al. (2010) Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methotrexate, and daily prednisone as therapy for metastatic breast cancer using vascular endothelial growth factor and soluble vascular endothelial growth factor receptor levels as markers of response. Journal of Clinical Oncology, 28, 723-730.

[11]   Landesberg, R., Woo, V., Cremers, S., et al. (2011) Potential pathophysiological mechanisms in osteonecrosis of the jaw. Annals of the New York Academy of Sciences, 1218, 62-79.

[12]   Yamashita, J. and McCauley, L.K. (2012) Antiresorptives and osteonecrosis of the jaw. Journal of Evidence-Based Dental Practice, 12, 233-247.